Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2

Science Signaling

Volumn 9, Issue 433, 2016, Pages

  Yeste, Ada ^a   Takenaka, Maisa C ^a   Mascanfroni, Ivan D ^a   Nadeau, Meghan ^a   Kenison, Jessica E ^a   Patel, Bonny ^a   Tukpah, Ann Marcia ^a   Babon, Jenny Aurielle B ^b   Denicola, Megan ^b   Kent, Sally C ^b   Pozo, David ^c,d   Quintana, Francisco J ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c CSIC   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYL HYDROCARBON RECEPTOR LIGAND 2 (1'H INDOLE 3' CARBONYL) THIAZOLE 4 CARBOXYLIC ACID METHYL ESTER; ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; NANOPARTICLE; PROINSULIN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; 2-(1'H-INDOLO-3'-CARBONYL)THIAZOLE-4-CARBOXYLIC ACID METHYL ESTER; AHR PROTEIN, HUMAN; AHR PROTEIN, MOUSE; AROMATIC HYDROCARBON RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; INDOLE DERIVATIVE; SOCS2 PROTEIN, HUMAN; SOCS2 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; THIAZOLE DERIVATIVE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL LINE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; MIDDLE AGED; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; AGONISTS; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; DIABETES MELLITUS, TYPE 1; HUMANS; INDOLES; INSULIN-SECRETING CELLS; MICE, INBRED NOD; NANOPARTICLES; RECEPTORS, ARYL HYDROCARBON; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, REGULATORY; THIAZOLES;

EID: 84975841205     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aad0612     Document Type: Article

References (69)

1. J. A. Bluestone, K. Herold, G. Eisenbarth, Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464, 1293-1300 (2010).
2. M. Wållberg, A. Cooke, Immune mechanisms in type 1 diabetes. Trends Immunol. 34, 583-591 (2013).
3. S. Z. Josefowicz, L.-F. Lu, A. Y. Rudensky, Regulatory T cells: Mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
4. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
5. A. Ferraro, C. Socci, A. Stabilini, A. Valle, P. Monti, L. Piemonti, R. Nano, S. Olek, P. Maffi, M. Scavini, A. Secchi, C. Staudacher, E. Bonifacio, M. Battaglia, Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60, 2903-2913 (2011).
6. A. Willcox, S. J. Richardson, A. J. Bone, A. K. Foulis, N. G. Morgan, Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 155, 173-181 (2009).
7. K. C. Herold, D. A. A. Vignali, A. Cooke, J. A. Bluestone, Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 13, 243-256 (2013).
8. L. T. Jeker, H. Bour-Jordan, J. A. Bluestone, Breakdown in peripheral tolerance in type 1 diabetes in mice and humans. Cold Spring Harb. Perspect. Med. 2, a007807 (2012).
9. J. A. Thompson, D. Perry, T. M. Brusko, Autologous regulatory T cells for the treatment of type 1 diabetes. Curr. Diab. Rep. 12, 623-632 (2012).
10. M. Battaglia, M.-G. Roncarolo, Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. Semin. Immunol. 23, 182-194 (2011).
11. R. J. Creusot, N. Giannoukakis, M. Trucco, M. J. Clare-Salzler, C. G. Fathman, It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes 63, 20-30 (2014).
12. Å. Lernmark, H. E. Larsson, Immune therapy in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 9, 92-103 (2013).
13. A. W. Michels, G. S. Eisenbarth, Immune intervention in type 1 diabetes. Semin. Immunol. 23, 214-219 (2011).
14. F. J. Quintana, G. Murugaiyan, M. F. Farez, M. Mitsdoerffer, A.-M. Tukpah, E. J. Burns, H. L. Weiner, An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 107, 20768-20773 (2010).
15. A. Yeste, M. Nadeau, E. J. Burns, H. L. Weiner, F. J. Quintana, Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 109, 11270-11275 (2012).
16. J. M. Benson, D. M. Shepherd, Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol. Sci. 124, 327-338 (2011).
17. A. Bessede, M. Gargaro, M. T. Pallotta, D. Matino, G. Servillo, C. Brunacci, S. Bicciato, E. M. C. Mazza, A. Macchiarulo, C. Vacca, R. Iannitti, L. Tissi, C. Volpi, M. L. Belladonna, C. Orabona, R. Bianchi, T. V. Lanz, M. Platten, M. A. Della Fazia, D. Piobbico, T. Zelante, H. Funakoshi, T. Nakamura, D. Gilot, M. S. Denison, G. J. Guillemin, J. B. DuHadaway, G. C. Prendergast, R. Metz, M. Geffard, L. Boon, M. Pirro, A. Iorio, B. Veyret, L. Romani, U. Grohmann, F. Fallarino, P. Puccetti, Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511, 184-190 (2014).
18. E. Hauben, S. Gregori, E. Draghici, B. Migliavacca, S. Olivieri, M. Woisetschläger, M. G. Roncarolo, Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 112, 1214-1222 (2008).
19. J. D. Mezrich, J. H. Fechner, X. Zhang, B. P. Johnson, W. J. Burlingham, C. A. Bradfield, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190-3198 (2010).
20. N. T. Nguyen, A. Kimura, T. Nakahama, I. Chinen, K. Masuda, K. Nohara, Y. Fujii-Kuriyama, T. Kishimoto, Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 107, 19961-19966 (2010).
21. G. Fousteri, A. Dave, A. Bot, T. Juntti, S. Omid, M. von Herrath, Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNγ. Diabetologia 53, 1958-1970 (2010).
22. B. O. Roep, M. Peakman, Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb. Perspect. Med. 2, a007781 (2012).
23. M. Nakayama, N. Abiru, H. Moriyama, N. Babaya, E. Liu, D. Miao, L. Yu, D. R. Wegmann, J. C. Hutton, J. F. Elliott, G. S. Eisenbarth, Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435, 220-223 (2005).
24. J. D. Katz, B. Wang, K. Haskins, C. Benoist, D. Mathis, Following a diabetogenic T cell from genesis through pathogenesis. Cell 74, 1089-1100 (1993).
25. B. Merchant, Gold, the noble metal and the paradoxes of its toxicology. Biologicals 26, 49-59 (1998).
26. 198 in man. Cancer 7, 856-866 (1954).
27. F. J. Quintana, P. Carmi, I. R. Cohen, DNA vaccination with heat shock protein 60 inhibits cyclophosphamide-accelerated diabetes. J. Immunol. 169, 6030-6035 (2002).
28. F. J. Quintana, P. H. Hagedorn, G. Elizur, Y. Merbl, E. Domany, I. R. Cohen, Functional immunomics: Microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc. Natl. Acad. Sci. U.S.A. 101 (Suppl. 2), 14615-14621 (2004).
29. M. A. Atkinson, G. S. Eisenbarth, A. W. Michels, Type 1 diabetes. Lancet 383, 69-82 (2014).
30. T. Delong, T. A. Wiles, R. L. Baker, B. Bradley, G. Barbour, R. Reisdorph, M. Armstrong, R. L. Powell, N. Reisdorph, N. Kumar, C. M. Elso, M. DeNicola, R. Bottino, A. C. Powers, D. M. Harlan, S. C. Kent, S. I. Mannering, K. Haskins, Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351, 711-714 (2016).
31. K. Haskins, M. Portas, B. Bergman, K. Lafferty, B. Bradley, Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 86, 8000-8004 (1989).
32. B. D. Stadinski, T. Delong, N. Reisdorph, R. Reisdorph, R. L. Powell, M. Armstrong, J. D. Piganelli, G. Barbour, B. Bradley, F. Crawford, P. Marrack, S. K. Mahata, J. W. Kappler, K. Haskins, Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 11, 225-231 (2010).
33. D. Ganguly, S. Haak, V. Sisirak, B. Reizis, The role of dendritic cells in autoimmunity. Nat. Rev. Immunol. 13, 566-577 (2013).
34. I. D. Mascanfroni, A. Yeste, S. M. Vieira, E. J. Burns, B. Patel, I. Sloma, Y. Wu, L. Mayo, R. Ben-Hamo, S. Efroni, V. K. Kuchroo, S. C. Robson, F. J. Quintana, IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14, 1054-1063 (2013).
35. A. Mildner, S. Jung, Development and function of dendritic cell subsets. Immunity 40, 642-656 (2014).
36. F. J. Quintana, A. Yeste, I. D. Mascanfroni, Role and therapeutic value of dendritic cells in central nervous system autoimmunity. Cell Death Differ. 22, 215-224 (2015).
37. F. J. Quintana, D. H. Sherr, Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol. Rev. 65, 1148-1161 (2013).
38. F. J. Quintana, LeA(H)Rning self-control. Cell Res. 24, 1155-1156 (2014).
39. D. R. Boverhof, E. Tam, A. S. Harney, R. B. Crawford, N. E. Kaminski, T. R. Zacharewski, 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces suppressor of cytokine signaling 2 in murine B cells. Mol. Pharmacol. 66, 1662-1670 (2004).
40. C. McBerry, R. M. S. Gonzalez, N. Shryock, A. Dias, J. Aliberti, SOCS2-induced proteasome-dependent TRAF6 degradation: A common anti-inflammatory pathway for control of innate immune responses. PLOS One 7, e38384 (2012).
41. H17 cell differentiation by the aryl hydrocarbon receptor. Nature 453, 65-71 (2008).
42. + T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes 53, 1987-1994 (2004).
43. J. P. Driver, D. V. Serreze, Y.-G. Chen, Mouse models for the study of autoimmune type 1 diabetes: A NOD to similarities and differences to human disease. Semin. Immunopathol. 33, 67-87 (2011).
44. D. Bending, H. De la Peña, M. Veldhoen, J. M. Phillips, C. Uyttenhove, B. Stockinger, A. Cooke, Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 119, 565-572 (2009).
45. J. H. Esensten, M. R. Lee, L. H. Glimcher, J. A. Bluestone, T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J. Immunol. 183, 75-82 (2009).
46. J. Joseph, S. Bittner, F. M. P. Kaiser, H. Wiendl, S. Kissler, IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. J. Immunol. 188, 216-221 (2012).
47. reg) dysfunction in NOD mice. Proc. Natl. Acad. Sci. U.S.A. 108, 8737-8742 (2011).
48. M. Feuerer, Y. Shen, D. R. Littman, C. Benoist, D. Mathis, How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31, 654-664 (2009).
49. D. Bresson, G. Fousteri, Y. Manenkova, M. Croft, M. von Herrath, Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J. Autoimmun. 37, 342-351 (2011).
50. Y. Grinberg-Bleyer, A. Baeyens, S. You, R. Elhage, G. Fourcade, S. Gregoire, N. Cagnard, W. Carpentier, Q. Tang, J. Bluestone, L. Chatenoud, D. Klatzmann, B. L. Salomon, E. Piaggio, IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207, 1871-1878 (2010).
51. S. Tsai, A. Shameli, J. Yamanouchi, X. Clemente-Casares, J. Wang, P. Serra, Y. Yang, Z. Medarova, A. Moore, P. Santamaria, Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity 32, 568-580 (2010).
52. + T cell dependent. J. Immunol. 187, 2859-2866 (2011).
53. S. Tsai, P. Serra, X. Clemente-Casares, R. M. Slattery, P. Santamaria, Dendritic cell-dependent in vivo generation of autoregulatory T cells by antidiabetogenic MHC class II. J. Immunol. 191, 70-82 (2013).
54. L. C. Kennedy, A. S. Bear, J. K. Young, N. A. Lewinski, J. Kim, A. E. Foster, R. A. Drezek, T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res. Lett. 6, 283 (2011).
55. L. Apetoh, F. J. Quintana, C. Pot, N. Joller, S. Xiao, D. Kumar, E. J. Burns, D. H. Sherr, H. L. Weiner, V. K. Kuchroo, The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. 11, 854-861 (2010).
56. I. D. Mascanfroni, M. C. Takenaka, A. Yeste, B. Patel, Y. Wu, J. E. Kenison, S. Siddiqui, A. S. Basso, L. E. Otterbein, D. M. Pardoll, F. Pan, A. Priel, C. B. Clish, S. C. Robson, F. J. Quintana, Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 21, 638-646 (2015).
57. R. Lang, A.-L. Pauleau, E. Parganas, Y. Takahashi, J. Mages, J. N. Ihle, R. Rutschman, P. J. Murray, SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4, 546-550 (2003).
58. R. Nakagawa, T. Naka, H. Tsutsui, M. Fujimoto, A. Kimura, T. Abe, E. Seki, S. Sato, O. Takeuchi, K. Takeda, S. Akira, K. Yamanishi, I. Kawase, K. Nakanishi, T. Kishimoto, SOCS-1 participates in negative regulation of LPS responses. Immunity 17, 677-687 (2002).
59. A. Mansell, R. Smith, S. L. Doyle, P. Gray, J. E. Fenner, P. J. Crack, S. E. Nicholson, D. J. Hilton, L. A. J. O'Neill, P. J. Hertzog, Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7, 148-155 (2006).
60. J. Strebovsky, P. Walker, R. Lang, A. H. Dalpke, Suppressor of cytokine signaling 1 (SOCS1) limits NFκB signaling by decreasing p65 stability within the cell nucleus. FASEB J. 25, 863-874 (2011).
61. J. Nishio, M. Feuerer, J. Wong, D. Mathis, C. Benoist, Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J. Exp. Med. 207, 1879-1889 (2010).
62. J. Hu, O. Winqvist, A. Flores-Morales, A.-C. Wikström, G. Norstedt, SOCS2 influences LPS induced human monocyte-derived dendritic cell maturation. PLOS One 4, e7178 (2009).
63. G. Posselt, H. Schwarz, A. Duschl, J. Horejs-Hoeck, Suppressor of cytokine signaling 2 is a feedback inhibitor of TLR-induced activation in human monocyte-derived dendritic cells. J. Immunol. 187, 2875-2884 (2011).
64. 4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. Med. 12, 330-334 (2006).
65. X. Clemente-Casares, S. Tsai, C. Huang, P. Santamaria, Antigen-specific therapeutic approaches in Type 1 diabetes. Cold Spring Harb. Perspect. Med. 2, a007773 (2012).
66. + T cells in type 1 diabetes. Sci. Transl. Med. 5, 191ra82 (2013).
67. D. R. Getts, A. J. Martin, D. P. McCarthy, R. L. Terry, Z. N. Hunter, W. T. Yap, M. T. Getts, M. Pleiss, X. Luo, N. J. C. King, L. D. Shea, S. D. Miller, Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30, 1217-1224 (2012).
68. H. B. Larman, U. Laserson, L. Querol, K. Verhaeghen, N. L. Solimini, G. J. Xu, P. L. Klarenbeek, G. M. Church, D. A. Hafler, R. M. Plenge, P. A. Nigrovic, P. L. De Jager, I. Weets, G. A. Martens, K. C. O'Connor, S. J. Elledge, PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. J. Autoimmun. 43, 1-9 (2013).
69. X. Qian, X.-H. Peng, D. O. Ansari, Q. Yin-Goen, G. Z. Chen, D. M. Shin, L. Yang, A. N. Young, M. D. Wang, S. Nie, In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotechnol. 26, 83-90 (2008).